logo

For the Inventor, By the Inventor

Rillieux-La-Pape, France

Richard Charvet

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:

goldMedal20 out of 42 
 
Adocia
 patents

Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 12186373 - Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid (2025-01-07),
2. 11883496 - Injectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (2024-01-30),
3. 11633460 - Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (2023-04-25),
4. 11576952 - Injectable solution at pH 7 comprising at least one basal insulin for which the pI is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (2023-02-14),
5. 11191812 - Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid (2021-12-07),
6. 11173109 - Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid (2021-11-16),
7. 11129877 - Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid (2021-09-28),
8. 10987426 - Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid (2021-04-27),
9. 10792335 - Rapid-acting insulin composition comprising a substituted citrate (2020-10-06),
10. 10583175 - Rapid-acting insulin formulation comprising a substituted anionic compound (2020-03-10),
11. 10548952 - Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (2020-02-04),
12. 10485851 - Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid (2019-11-26),
13. 10449256 - Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer (2019-10-22),
14. 10383920 - Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (2019-08-20),
15. 9795678 - Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound (2017-10-24),

Title: Richard Charvet: Innovator in Injectable Solutions for Diabetes Management

Introduction

Richard Charvet, based in Rillieux la Pape, France, is an accomplished inventor with a noteworthy portfolio of 20 patents. His work primarily focuses on creating innovative compositions for injectable aqueous solutions that are pivotal in diabetes management. Through his novel approaches, he has significantly contributed to advancements in insulin therapies.

Latest Patents

Among his latest patents are compositions designed to improve the delivery of amylin and insulin. One patent describes an injectable aqueous solution comprising amylin, an amylin agonist receptor, or an analogue, along with a co-polyamino acid. This distinctive formulation maintains a pH of 6.0 to 8.0 and interestingly excludes basal insulin having an isoelectric point (IP) from 5.8 to 8.5. Another remarkable invention includes a physically stable solution featuring a basal insulin with an appropriate isoelectric point and hydrophobic components integrated into its structure.

Career Highlights

Richard Charvet’s innovative spirit has led him to work at Adocia, a company renowned for its cutting-edge research in biopharmaceutical solutions for diabetes. His passion for improving patient outcomes through advanced drug delivery systems has been instrumental in enhancing existing therapeutic options.

Collaborations

Throughout his career, Richard has collaborated with talented individuals such as Olivier Soula and Alexandre Geissler. These partnerships have allowed for a fusion of ideas and expertise, driving forward the company’s mission to develop more effective diabetes treatments.

Conclusion

In summary, Richard Charvet stands out as a significant inventor in the field of injectable solutions for diabetes management. His 20 patents underscore his commitment to innovation, and his work at Adocia continues to pave the way towards better therapeutic options for patients. Through collaboration and ingenuity, Richard Charvet exemplifies the impact of dedicated inventors in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…